ReviewJournal of cardiovascular development and disease2021
Better Medications Adherence Lowers Cardiovascular Events, Stroke, and All-Cause Mortality Risk: A Dose-Response Meta-Analysis.
Review in Journal of cardiovascular development and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- A systematic review of medication adherence and mortality in chronic disease: Implications for clinical guidelines and policy.British journal of clinical pharmacology · 2026Pooled it
- Risk of Adverse Health Outcomes in Patients with Poor Adherence to Cardiovascular Medication Treatment: A Systematic Review.Arquivos brasileiros de cardiologia · 2024Pooled it
- Impacts of medication non-adherence to major modifiable stroke-related diseases on stroke prevention and mortality: a meta-analysis.Journal of neurology · 2023Pooled it
- Predictors of Medication Adherence Among Taiwanese Community-Based Adults with Hypertension: The Application of Temporal Self-Regulation Theory.Behavioral sciences (Basel, Switzerland) · 2026Article
- Associations between social determinants and poor hypertension treatment adherence among middle-aged and older people in rural China: a hospital-based case‒control study.BMC public health · 2026Article
- Milk-derived extracellular vesicles in cardiovascular therapy: emerging biological functions and therapeutic perspectives.Frontiers in bioengineering and biotechnology · 2026Review
- Article
- Prediction of cardiovascular risk using machine-learning methods. Sex-specific differences.Frontiers in cardiovascular medicine · 2025Article
- Pharmacist-supported electronic outreach to address medication nonadherence for Medicare Advantage enrollees.Journal of managed care & specialty pharmacy · 2025Article
- Projected Cost Savings With Optimal Medication Adherence in Patients With Cardiovascular Disease Requiring Lipid-Lowering Therapy: A Multinational Economic Evaluation Study.Journal of the American Heart Association · 2024Article
- Nonadherence to Cardiovascular Drugs Predicts Risk for Non-Arthritic Anterior Ischemic Optic Neuropathy: A Large-Scale National Study.Journal of clinical medicine · 2024Article
- Facilitators and Barriers of Incremental Innovation by Fixed Dose Combinations in Cardiovascular Diseases.Journal of cardiovascular development and disease · 2024Article
- Level of medication adherence and its determinants of cardiovascular disease patients attending at specialized teaching hospitals of Amhara regional state, Ethiopia: a multicenter cross-sectional study.Frontiers in pharmacology · 2024Article
- Achievement of LDL-Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA-AP Study: LDL-Cholesterol Goals in Primary Care.Cardiovascular therapeutics · 2024Observational
- 2022 Renal denervation therapy for the treatment of hypertension: a statement from the Thai Hypertension Society.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Advances in Neurological Diseases and Stroke.Journal of cardiovascular development and disease · 2023Article
- Cardiovascular Risk in Patients with Dyslipidemia and Their Degree of Control as Perceived by Primary Care Physicians in a Survey-TERESA-Opinion Study.International journal of environmental research and public health · 2023Article
- Impact of the COVID-19 Pandemic on the Therapeutic Continuity among Outpatients with Chronic Cardiovascular Therapies.International journal of environmental research and public health · 2022Article
- mHealth App to improve medication adherence among older adult stroke survivors: Development and usability study.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWe investigated the association between vascular medication adherence, assessed by different methods, and the risk of cardio-cerebrovascular events and all-cause mortality.
methodsA meta-analysis with a systematic search of PubMed, Web of Science, EMBASE, and Cochrane databases from inception date to 21 June 2021 was used to identify relevant studies that had evaluated the association between cardiovascular medication adherence levels and cardiovascular events (CVEs), stroke, and all-cause mortality risks. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using a random-effects meta-analysis. Restricted cubic splines were used to model the dose-response association.
resultsWe identified 46 articles in the dose-response meta-analysis. The dose-response analysis indicated that a 20% increment in cardiovascular medication, antihypertensive medication, and lipid-lowering medication adherence level were associated with 9% (RR: 0.91, 95% CI 0.88-0.94), 7% (RR 0.93, 95% CI: 0.84-1.03), and 10% (RR 0.90, 95% CI: 0.88-0.92) lowers risk of CVEs, respectively. The reduced risk of stroke respectively was 16% (RR: 0.84, 95% CI: 0.81-0.87), 17% (RR 0.83, 95% CI: 0.78-0.89), and 13% (RR 0.87, 95% CI: 0.84-0.91). The reduced risk of all-cause mortality respectively was 10% (RR: 0.90, 95% CI: 0.87-0.92), 12% (RR 0.88, 95% CI: 0.82-0.94), and 9% (RR 0.91, 95% CI: 0.89-0.94).
conclusionsA better medication adherence level was associated with a reduced risk of cardio-cerebrovascular events and all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.